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Abstract In 1996, a new method, termed the yeast three-hy-
brid system, dedicated to selection of RNA binding proteins
using a hybrid RNA molecule as bait was described. In this
minireview, we summarize the results that have been obtained
using this method. Indeed, V20 unknown proteins have been
characterized so far. The three-hybrid strategy has also been
used as a tool to dissect RNA^protein interactions. The example
of such a study on human histone HBP interaction with its
target mRNA is described. Problems that can be encountered
are addressed in a troubleshooting section. Especially, our re-
sults with tRNA binding proteins are discussed.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
In the cell, the interactions of RNAs with their protein
partners play a pivotal role in a wide variety of fundamental
biological processes (e.g. splicing, translational control, and
transport to speci¢c compartments). Several methods have
been devised to detect RNA^protein interactions; one of these
is the yeast three-hybrid system (also called the tri-hybrid
system [1]), which has been developed simultaneously by
two groups [1,2]. In this report we summarize the results ob-
tained during the past seven years using this method. For
some RNA binding proteins, the yeast three-hybrid strategy
is useless and the reasons for that are discussed.
2. Principle of the yeast three-hybrid system
This method consists in the expression in yeast cells of three
chimerical molecules, which assemble in order to activate two
reporter genes. Thus, using the yeast three-hybrid system, in
contrast to other methods, RNA^protein interactions are de-
tected in vivo. This system uses a transactivator protein in
yeast, such as Gal4p, that is able to recruit the transcriptional
machinery and trigger transcription of a gene. It consists of a
DNA binding domain (DB) and an activation domain (AD)
and, importantly, these two domains are functionally indepen-
dent, meaning that they can be inserted into other molecules.
In the yeast three-hybrid system the DNA binding domain
(LexADB or Gal4DB) is fused to an RNA binding protein
(MS2-coat protein or Hiv-1 RevM10) (Fig. 1a). The second
fusion protein contains on one hand the Gal4 activation do-
main (Gal4AD) and on the other hand the RNA binding
protein ‘Y’ of interest. The two fusion proteins are bridged
by a third hybrid RNA molecule containing the binding site
for the ¢rst RNA binding protein (MS2 or RRE) and the
binding site ‘X’ for the RNA binding protein ‘Y’ studied.
Binding of protein ‘Y’ to the RNA binding site ‘X’ will create
a functional transactivator, which is tethered at the upstream
activating sequence of two reporter genes (HIS3 and lacZ)
that will be transcribed and expressed by yeast cells. The ex-
pression level of lacZ gene can be determined in vitro by
measuring the L-galactosidase activity, or visualized in vivo
by plating the yeast transformants on media supplemented
with X-Gal. On the other hand, HIS3 is the gene encoding
imidazoleglycerol-phosphate dehydratase (His3p) and its ex-
pression confers the ability to grow on a medium lacking
histidine. 3-amino-1,2,4-triazole (3-AT) is a competitive inhib-
itor of HIS3 gene product, and therefore cells containing
more His3p can survive at higher concentrations of 3-AT in
the medium. Thus, the level of 3-AT resistance of the yeast
cells re£ects the HIS3 expression level and consequently the
strength of the RNA^protein interaction in the yeast three-
hybrid context. This also means that the stringency of the
selection can be adjusted to the type of RNA^protein couple
of interest by changing the concentration of 3-AT in the me-
dium. In the system developed by SenGupta et al. [2] the ¢rst
hybrid molecule LexADB-MS2 is encoded by the genome of
the yeast strain L-40 coat and the fusion protein Y-Gal4AD is
expressed from a plasmid (Fig. 1a). The hybrid RNA mole-
cule is produced by RNA polymerase III leading to an RNA
containing the RNAse P 5P leader sequence and 3P trailer se-
quence leading to nuclear localization (Fig. 1b). One major
drawback of RNA polymerase III is that stretches of four or
more T residues act as transcription terminator. Unfortu-
nately, many RNA binding proteins recognize U-rich RNA
targets and RNA polymerase III is not able to transcribe such
RNAs. In the method developed by Putz et al. [1], the three
components of the system are expressed from two plasmids
(Fig. 1a) allowing the use of any previously described yeast
strains for two-hybrid system that provide the two reporter
genes HIS3 and lacZ under the control of a Gal4 operator.
Another di¡erence concerns the hybrid RNA molecule, which
is transcribed by RNA polymerase II, avoiding any premature
stop in the transcription of U-rich target RNAs.
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3. Cloning the genes of uncharacterized proteins or RNA
targets
The three-hybrid system has been used to clone genes en-
coding uncharacterized RNA binding proteins. In this pur-
pose the RNA targets of those unknown proteins have been
used as bait in the screening of a cDNA expression library.
The yeast three-hybrid system has been used successfully and
allowed the characterization of about 20 proteins (see Table 1,
upper part). All these screenings have been done with the
method described by SenGupta et al. [2]. Among these, sev-
eral screenings led to the characterization of the sought pro-
tein partners using RNA baits such as 5P or 3P UTR of cel-
lular or viral mRNA. These proteins are involved in
regulation of protein expression in the cell by in£uencing var-
ious steps of mRNA metabolism such as 5P and 3P processing,
nuclear-cytoplasmic shuttling, translation and stability [3^14].
In addition, two proteins (CUG-BP and XB1), that bind in-
trons during the splicing process have been characterized
[15,16]. These newly identi¢ed interaction partners could be
con¢rmed by functional assays or other methods like electro-
mobility shift assays, UV cross-linking or immunoprecipita-
tions experiments.
In some selections, other proteins than the expected ones
were selected for interacting with the bait. These unexpected
proteins provided new perspectives on the function of the
RNA binding protein of interest. Three-hybrid screens with
the human telomerase RNA led to selection of two proteins,
which are the protein hStau and more surprisingly the ribo-
somal protein L22 [17]. In the case of xenopus histone 3P
UTR, two proteins have been selected and named SLBP1
and SLBP2 [6]. They share a conserved RNA binding domain
in the middle of the peptide sequence but di¡er outside of this
domain. SLBP1 participates in histone pre-mRNA 3P process-
ing in the nucleus whereas SLBP2 is oocyte-speci¢c and does
not support pre-mRNA 3P processing but is used to store
maternal histone mRNA in a latent state until fertilization.
Another example comes from the vimentin 3P UTR bait that
led to the selection of two proteins, HAX-1 and EF1-Q [14].
The authors showed that EF1-Q is present in a larger complex
with the target RNA that can be separated from the HAX-1-
vimentin mRNA complex. EF1-Q is involved in the coordina-
tion of vimentin mRNA translation with respect to the cell
cycle and HAX-1 is required for the localization of vimentin
mRNA at the periphery of the cell. In this case, the yeast
three-hybrid system allowed the selection of two proteins in-
volved in two di¡erent steps of the vimentin mRNA metabo-
lism. Several groups have modi¢ed the yeast three-hybrid sys-
tem in order to characterize protein components of RNP
complexes (Table 1, middle part). In this new system the hy-
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Fig. 1. a: The yeast three-hybrid system protein and RNA compo-
nents described by SenGupta et al. [2] (upper panel) and by Putz et
al. [1] (lower panel). The RNA and protein hybrids are encoded ei-
ther by the genome of the yeast strain used or by a set of di¡erent
plasmids that are indicated on the schemes. b: In the system devel-
oped by SenGupta et al. [2], the RNA bait X can be inserted 5P or
3P of the MS2 binding sites. On the contrary, the plasmid pRevRX
of the tri-hybrid system from Putz et al. [1] expresses a hybrid
RNA where the bait was fused to the 3P terminus of RRE-RNA
(not shown). c: New hybrid system using an RNA^protein complex
X^Y as bait to select new interactors Z.
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brid RNA molecule is not used and LexADB is fused with the
protein of interest complexed with its RNA target (Fig. 1c).
New RNP binding proteins are then selected from a cDNA
library for their ability to form a three-hybrid complex. The
¢rst example of such a selection was done with the complex
Ro60-hYRNA, which allowed the selection of RoBP [18,19].
Then the complex SLBP-histone hairpin RNA was used to
select the protein ZFP100 [20]. Similarly, She3p has been
characterized as an ash 3P UTR binding protein by three-hy-
brid screens and then the complex She3p-ash RNA has been
used to select She2p [12]. The complex formed by Hiv-1 TAR-
Tat has been used as bait by two groups and led to the
selection of two di¡erent proteins, cyclin T1 [21] and Tip110
[22]. Finally, the hunchback mRNA binding proteins have
been extensively studied using these alternative hybrid-screen-
ing approaches. In a ¢rst step the complex Pumilio-hunchback
mRNA (fragment NRE) has been used to select the protein
nanos [23]. The second step was to use the ternary complex
Pumilio-NRE-nanos as bait for the selection of the protein
Brat [24], this is the ¢rst example reported of a yeast four-
hybrid system encompassing three proteins and an RNA mol-
ecule.
It is also possible to use the yeast three-hybrid system the
other way around which means using a protein as bait to
select RNA molecules able to bind to that protein (Table 1,
bottom part). The yeast protein Snp1 has been used to vali-
date the screening strategy and allowed to select its cognate
interactor U1 snRNA [25]. In another study the mouse
hnRNP K has been used to screen a human RNA library
and among the selected clones, a signi¢cant part of these
are encoded by the mitochondrial genome, suggesting that
hnRNP K is involved in expression of mitochondrial genes,
which was completely unexpected [26].
4. The three-hybrid system as a tool to dissect RNA^protein
interactions
This method has also been used to test the interaction of
previously known or suspected interactors. Table 2 lists all the
RNA^protein couples successfully used in the three-hybrid
Table 1
A non-exhaustive list of unknown proteins and RNAs characterized using the yeast three-hybrid system
RNA length (nt) Plasmid used Protein Y Protein length (aa) [3-AT] (mM) Reference
RNA X
Hairpin of histone 3P UTR mRNA 35 pIII/MS2.1 SLBP 270^274^253 5 [3]
Hairpin of histone 3P UTR mRNA 34 pIII/MS2.2 HBP (SLBP) 270 25 [4]
fem-3 3P UTR PME 74 pIII/A/MS2.2 FBF1 493a 5 [5]
FBF2 630
Hairpin of histone 3P UTR mRNA 35 pIII/MS2.1 SLBP1 254 5 [6]
SLBP2 250
Nanos 3P UTR TCE A 29 pIII/MS2.1 Smaug 860a 3 [7]
In£uenza NP 5P UTR 45 pIII/MS2.1 GRSF-1 331 3 [8]
tra-2 3P UTR TGE 60 pIII/MS2.2 GLD-1 463 5 [9]
NF-IL6 mRNA 3P UTR (element D1) 75 pIII/A/MS2.2 unnamed protein 70 5 [10]
Human telomerase hTR 158 pIII/MS2.2 L22 128 5 [17]
hStau 448a
Prm1 3P UTR 37 pIII/MS2.2 MSY4 358a 5 [11]
APP splicing enhancer 21 pIII/A/MS2.1 CUG-BP 226 5 [15]
SiahBP 547
ash1 3P UTR (element E3) 127 pIII/A/MS2.2 She3p 189a 1 [12]
ash1 3P UTR (element E1+E3) 153^127 pIII/A/MS2.2 Loc1p 204 5 [27]
Hepatitis C HCV 3PX 98 pIII/A/MS2.1 L22 128 2^5 [13]
L3 403
S3 158
mL3 348
Trypanosoma cruzi SL RNA 111 pIII/A/MS2.1 XB1 354 2.5 [16]
pre-rRNA 54 pIII/A/MS2.1 Fibrillarin 305 3 [28]
Vimentin 3P UTR 69 pIII/A/MS2.1 HAX-1 279 2^50 [14]
eEF-1Q 437
hRIP 288
RNA X+protein
hY5RNA+Ro60 84 pIII/MS2.1 RoBP1 559 1 [18,19]
Histone 3PUTR mRNA+SLBP 34 pIII/MS2.1 ZFP100 871 0^5 [20]
ash1 3P UTR (E3)+She3p 127 pIII/A/MS2.2 She2p 246 1 [12]
TAR+Tat 58 pIII/A/MS2.2 cyclin T1 726 b [21]
TAR+Tat 58 pIII/MS2.2 Tip110 963 b [22]
hb RNA (NRE)+Pumilio 64 pIII/MS2.1 Nanos 335a 0^7 [23]
hb RNA (NRE)+Pumilio+Nanos 64 pIII/MS2.1 Brat 330a 3 [24]
RNA selected with a bait protein
U1 SL RNA 45 pIII/MS2.2 Snp1 300 0.5 [25]
mt RNAs 50^150 pIII/MS2.2 mouse hnRNP K 464 2.5 [26]
The upper part of the table lists the proteins selected with an RNA bait, the middle part of the table lists the proteins isolated with baits en-
compassing RNA^protein complexes and the bottom part of the table lists the RNA selected with bait proteins. Plasmids used for expressing
the hybrid RNA are indicated. The RNA baits are located 5P or 3P of the MS2 binding site depending on the plasmid used (see also Fig. 1b).
RNA baits expressed from pRevRX are located 3P of the RRE. Plasmids pRH5P and pRH3P are vectors from a commercially available kit
(RNA-Protein Hybrid Hunter Kit, Invitrogen) based on vectors described by SenGupta et al. [2].
aIncomplete cDNA selected.
bOnly lacZ used.
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strategy. After designing the yeast three-hybrid system, the
authors had to test the reliability of the method with several
RNA^protein couples known to interact with each other. Putz
et al. validated their method by the detection of the HIV-1
complex RevM10-RRE [1] whereas SenGupta et al. [2] veri-
¢ed interaction with the couples Tat-TAR and IRP-IRE [2].
Another application is to de¢ne the minimal binding domains
by deletion and mutational analysis of the RNA and/or the
protein. By combinatorial approaches with randomly muta-
genized RNA or protein library, the RNA binding speci¢city
could also be analyzed [26,29^31]. This strategy has been used
extensively in our laboratory to study the binding of HBP
(also called SLBP) on the hairpin of the 3P UTR replica-
tion-dependent histone mRNA [31] and [63]. Thus, we could
select single mutations in HBP that abolish binding to the
wild-type histone hairpin. Interestingly, all the mutations
mapped to the central RNA binding domain (RBD; Fig. 2).
Then, we selected with the yeast three-hybrid system intra-
genic mutations able to restore the binding on a histone hair-
pin. Remarkably, most of the compensating mutations are
located outside of this central domain. These results allowed
us to propose a set of putative internal interactions between
several residues of the RBD and its £anking domains (Fig. 2).
To conclude, the yeast three-hybrid system has been a very
fruitful method for the study of the interaction of HBP with
its target RNA and the organization of HBP domains.
Table 2
A non-exhaustive list of the RNA^protein interactions studied with the yeast three-hybrid system and characterization of previously assumed
interactors or identi¢cation of critical residues involved in the speci¢c recognition of RNA and proteins
RNA X RNA length (nt) Plasmid used Protein Y Protein length (aa) [3-AT] (mM) Reference
RRE 240 pRevRX RevM10 116 30 [1]
IRE 51 pIII/MS2.2 IRP1 889 20 [2]
TAR 58 pIII/MS2.2 Tat 86 20 [2]
MPMV CTEa 153 pIII/MS2.1 TAP 619 b [29]
RSV Mia 160 pIII/A/MS2.1 RSV Gag 577 b [30]
Hairpin of histone 3P UTR mRNA 34 pIII/MS2.2 HBPa 270 0^225 [31]
mTR 393 pIII/A/MS2.2 TP1 871c 5 [32]
HIV-1 RNA encapsidation signal 139 pIII/MS2.2 HIV-1 Gag 243 b [33]
HIV-1TAR 55 pIII/MS2.2 Tat 86 b [34]
HIV-1, HIV-2 and SIVmnd TAR 55^126^128 pIII/MS2.2 Tat 86 b [35]
RPS14B pre-mRNA-18S rRNA 59^70 pIII/MS2.1 S14 138 5^20 [36]
hvg1-hvg2-hvg4 96^86^99 pIII/MS2.1 mTEP1 871c 10 [37]
RSV Mi 160 pIII/MS2.1 RSV Gag 701 b [38]
HERV-K RRE 433 pIII/MS2.2 HERV-K Rev 105 b [39,40]
Nanos TCE-TCEIIIA 96 pIII/A/MS2.1 Smaug 483 b [41]
BRE-BREM 48^48 pIII/MS2.1 xlBrunoL3 538 b [42]
CaMV pgRNA 87 pIII/MS2.2 CaMV CP 454 b [43]
SL RNA 145 pIII/MS2.1 TSR1IP 354c 0.1 [44]
CD44 exon V5 210 pRH5P hnRNPA1 320 b [45]
cob intron bl4 over 1600 pRH3P bl4 maturase 638 5 [46]
LeuRS 885
Long CUG repeats and UG repeats variable pIII/A/MS2.2 CUG-BP 226 b [47]
UG repeats variable CUG-BP+LYLQ 230 b [47]
NF-KB 31 pIII/A/MS2.2 ap50 460 1^2 [48]
hY1 and hY3 112^105 pRH5P hnRNP I 531 b [49]
hnRNP K 464
Prm1 3P UTR 37 pIII/MS2.2 MSY2-MSY4 262^282 5 [50]
H1 RNA 497 pRH3P Rpp21 154 5 [51]
Rpp29 220
Rpp30 268
Rpp38 283
DTE of MAP2 3P UTR 640 pRevRX rStaufen 495 10 [52]
HO 3P UTR 134 pIII/A/MS2.1 Mpt5 859 0 [53]
RPR1 P3 54 pIII/A/MS2.2 Pop1 875 1^20 [54]
hb NRE 32 pRH5P PfPuf1 286c b [55]
fem-3 PME-NRE-HO 3PUTR 74^64^134 pIII/A/MS2.2 FBF-1 451c b [56]
GLD-3 949 b
dmPUM 335c b
RPR1 P3 369 pIII/MS2.2 Pop1 875 20 [57]
Pop4 279
Hairpin of histone 3P UTR mRNA 34 pIII/MS2.1 CDL-1 367 5 [58]
PDGF2 5PUTR 127^322 pRevRX hnRNP-C1 290 0.5^100 [59]
hnRNPC2 303
bcl-2 ARE 107 pIII/A/MS2.1 AUF1 257 3 [60]
cob intron bl4 over 1600 pRH3P LeuRS 375 5 [61]
Hairpin of histone 3P UTR mRNA 34 pIII/MS2.2 HBPa 270 0^100 [63]
A. aeolicus tRNALeu 98 pIII/A/MS2.2 LeuRS(L su) 289 25 E.D. Wang
The plasmids used for expressing the hybrid RNA are indicated as in Table 1.
aRandom mutagenesis.
bOnly lacZ used.
cIncomplete cDNA selected.
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5. Limits of the system
Unfortunately, the three-hybrid strategy can be useless for
some RNA^protein couples. For instance, since protein and
RNA partners are expressed as chimerical molecules, the fold-
ing or the accessibility of the bait might be disturbed by the
other moiety of the molecule. The hybrid RNA might also be
cut in the nucleus by a processing machinery leading to a
truncated hybrid RNA, useless for the three-hybrid strategy.
Some RNA molecules contain targeting signals that allow
their localization in organelles. These RNAs are not suitable
for three-hybrid studies since when the hybrid RNA is tar-
geted into these organelles the assembly of the three-hybrid
upstream of the reporter genes in the nucleus becomes impos-
sible. Several RNAs contain post-transcriptional modi¢ca-
tions necessary for binding to proteins. These RNAs and pro-
teins cannot be studied with the yeast three-hybrid system
since the hybrid RNA may be partially or not modi¢ed at
all. On top of that, many proteins need cofactors to bind to
their RNA partner and these cofactors might not be available
in the nucleus because they are located in another compart-
ment of the cell. Finally, some proteins bind to their target
RNA in a transient manner and with low a⁄nity, avoiding
detection of any complex with the three-hybrid strategy. An-
other drawback of the three-hybrid strategy is that the RNA^
protein interaction takes place in vivo, where it can be in£u-
enced by many cellular parameters. This leads to false-positive
clone predominance that must be eliminated by additional
time-consuming screening tests. Other techniques like SELEX
[64], plaque-lift assays [65] or T7 phage display [66] have been
used to detect RNA^protein interactions in vitro, which make
all the binding parameters controllable.
Indeed, we encountered some of these problems when we
wanted to select new tRNA binding proteins with the yeast
three-hybrid system. As a control we tested the interaction of
our bait tRNAs (yeast tRNAArg3 and tRNATyr2) with their
cognate aminoacyl-tRNA synthetases (yeast ArgRS and
TyrRS), the yeast tRNA transporter Los1p and the yeast
elongation factor EF1-K, but no positive signal could be de-
tected. It seems therefore that the tRNA is not a suitable bait
for the yeast three-hybrid system for one of the reasons de-
tailed previously. To our knowledge, the only functional
three-hybrid system isolated from a couple of tRNA and ami-
noacyl-tRNA synthetase remains tRNALeu and LeuRS from
Aquifex aeolicus. This interaction is highly speci¢c as judged
by the negative results obtained with other tRNAs or other
proteins like Los1p, EF1-K or Escherichia coli LeuRS (E.D.
Wang, personal communication).
6. Prospects
The yeast three-hybrid strategy has been widely used to
select unknown proteins and RNA partners and also for
studying RNA^protein interactions of previously assumed in-
teractors (Tables 1 and 2). This method has been successful
for RNAs of variable size (21^1600 nucleotides) [46,61]. There
is no general rule for the position of the bait in the hybrid
RNA since plasmids encoding hybrid RNA containing the
bait either internally or at the 3P end have been used success-
fully (Tables 1 and 2). The protein partners are also of vari-
able size ranging from very small subdomains like the 70 aa
NF-IL6 mRNA binding protein to very large proteins like Tip
110, which is 963 aa long. The use of 3-AT in the medium
allows modulating of the stringency of the screen. Indeed
when looking at strong interactions, up to 225 mM can be
used as it was done for HBP [31], which binds tightly to its
target RNA (Kd = 1.5U1039 M [62]). Reducing the 3-AT con-
centration or even omission of this drug from the medium
allows studying relatively weak interactions with Kd values
in the WM range (S14 on 18S rRNA: Kd = 3U1036 M [36]).
Future developments of the hybrid screenings will be to select
protein partners binding to bait consisting of RNP complexes.
This has already been done in the case of the hunchback
mRNA [23,24] and could be applied to many other com-
plexes. By varying the stringency of the selection, character-
ization of di¡erent protein partners binding tightly or weakly
will be possible. Most of RNP complexes consist of a core
composed of strong interactors surrounded by weak interac-
tors modulating the activity of the RNP. Three-hybrid screens
will allow sort of pealing of the RNP complexes. This will also
enable to select proteins binding to RNA at di¡erent steps of
their function. Once the proteins are characterized, one can
analyze the RNA^protein complexes by making positive and
negative selections on randomly mutated libraries of the two
partners. Importantly, interaction studies in the yeast three-
hybrid system should always be completed by other tests like
functional assays, in vitro binding studies or immunoprecipi-
tations in order to avoid artefacts.
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